BR112023020922A2 - Composição farmacêutica, uso da composição farmacêutica, método para tratar câncer em um paciente em necessidade do mesmo, e método para inibir o crescimento de células cancerígenas - Google Patents

Composição farmacêutica, uso da composição farmacêutica, método para tratar câncer em um paciente em necessidade do mesmo, e método para inibir o crescimento de células cancerígenas

Info

Publication number
BR112023020922A2
BR112023020922A2 BR112023020922A BR112023020922A BR112023020922A2 BR 112023020922 A2 BR112023020922 A2 BR 112023020922A2 BR 112023020922 A BR112023020922 A BR 112023020922A BR 112023020922 A BR112023020922 A BR 112023020922A BR 112023020922 A2 BR112023020922 A2 BR 112023020922A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
inhibiting
patient
growth
need
Prior art date
Application number
BR112023020922A
Other languages
English (en)
Portuguese (pt)
Inventor
Chun-Chung Wang
Lu-Tzu Chen
Ming-Tain Lai
wan-fen Li
Original Assignee
Obi Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Pharma Inc filed Critical Obi Pharma Inc
Publication of BR112023020922A2 publication Critical patent/BR112023020922A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/22—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112023020922A 2021-04-28 2021-04-28 Composição farmacêutica, uso da composição farmacêutica, método para tratar câncer em um paciente em necessidade do mesmo, e método para inibir o crescimento de células cancerígenas BR112023020922A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/029552 WO2022231580A1 (en) 2021-04-28 2021-04-28 Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor

Publications (1)

Publication Number Publication Date
BR112023020922A2 true BR112023020922A2 (pt) 2023-12-12

Family

ID=83847212

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020922A BR112023020922A2 (pt) 2021-04-28 2021-04-28 Composição farmacêutica, uso da composição farmacêutica, método para tratar câncer em um paciente em necessidade do mesmo, e método para inibir o crescimento de células cancerígenas

Country Status (10)

Country Link
US (1) US20240216401A1 (https=)
EP (1) EP4329745A4 (https=)
JP (1) JP2024515809A (https=)
KR (1) KR20240004519A (https=)
CN (1) CN117729917A (https=)
AU (1) AU2021443620A1 (https=)
BR (1) BR112023020922A2 (https=)
CA (1) CA3216896A1 (https=)
IL (1) IL307974A (https=)
WO (1) WO2022231580A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119744168A (zh) * 2022-09-09 2025-04-01 深圳艾欣达伟医药科技有限公司 Ast-3424联用治疗白血病及淋巴瘤
WO2025026214A1 (zh) 2023-07-28 2025-02-06 深圳艾欣达伟医药科技有限公司 治疗p53基因突变或缺陷阴性癌症、肿瘤患者
CN121646469A (zh) 2023-09-05 2026-03-10 深圳艾欣达伟医药科技有限公司 Ast-3424治疗癌症、肿瘤的给药方案及制药用途
CN121049512A (zh) * 2024-05-28 2025-12-02 深圳艾欣达伟医药科技有限公司 Ast-3424治疗肝癌

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5922791B2 (ja) * 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
WO2015125652A1 (ja) * 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
EP3390415B1 (en) * 2015-11-16 2020-02-26 Obi Pharma, Inc. (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
JP7194022B2 (ja) * 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
TW201919644A (zh) * 2017-09-29 2019-06-01 台灣浩鼎生技股份有限公司 治療血癌的方法
US11098002B2 (en) * 2019-07-26 2021-08-24 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease

Also Published As

Publication number Publication date
WO2022231580A1 (en) 2022-11-03
EP4329745A4 (en) 2025-03-19
CN117729917A (zh) 2024-03-19
AU2021443620A1 (en) 2023-10-26
CA3216896A1 (en) 2022-11-03
JP2024515809A (ja) 2024-04-10
KR20240004519A (ko) 2024-01-11
US20240216401A1 (en) 2024-07-04
IL307974A (en) 2023-12-01
EP4329745A1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
BR112023020922A2 (pt) Composição farmacêutica, uso da composição farmacêutica, método para tratar câncer em um paciente em necessidade do mesmo, e método para inibir o crescimento de células cancerígenas
Mendel et al. Therapy with hyperbaric oxygen and cefazolin for experimental osteomyelitis due to Staphylococcus aureus in rats
BR0313197A (pt) Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
Cuce et al. Treatment of paracoccidioidomycosis, candidiasis, chromomycosis, lobomycosis, and mycetoma with ketoconazole
BR112012030261B1 (pt) formulação farmacêutica tópica
MX2025010920A (es) Compuestos quimicos
Wenke et al. Effectiveness of commercially-available antibiotic-impregnated implants
ATE527254T1 (de) Mit imidazol enthaltenden sekundären aminen substituierte benzopyran-derivate, deren herstellung und diese enthaltende pharmazeutische zubereitungen
AR008387A1 (es) Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas
Latimer et al. Effects of hyperbaric oxygen therapy on uncomplicated incisional and open wound healing in dogs
BR112023016320A2 (pt) Composição terapêutica e método de combinação de imunoterapia multiplex com vacina contra câncer para tratamento de câncer
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
Saleh et al. Can dressings soaked with polyhexanide reduce bacterial loads in full-thickness skin grafting? A randomized controlled trial
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
BR112023022647A2 (pt) Derivado de 7-nitro-8-hidroxiquinolina, método de preparação do mesmo e uso médico do mesmo
Frank et al. Traumatic shock: XXI. Effectiveness of an antibiotic in experimental hemorrhagic shock
Stanger et al. Management of chronic osteomyelitis of the tibia with life‐threatening complications under negative pressure wound therapy and isolation of Helcococcus kunzii
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
AR133951A1 (es) Inhibidores de smarca2 útiles para el tratamiento de cánceres deficientes en smarca4
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
Zawaski et al. Radiation combined injury models to study the effects of interventions and wound biomechanics
Reich et al. Sporicidal efficacy of genipin: a potential theoretical alternative for biomaterial and tissue graft sterilization
Mendel et al. Synergy of HBO^ sub 2^ and a local antibiotic carrier for experimental osteomyelitis due to staphylococcus aureus in rats
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
Schmidt et al. Cytostatic resistance profile of the sulfur mustard resistant keratinocyte cell line HaCaT/SM